Align Technology Inc Dossier - Source-backed chat

Align Technology Inc

ALGNNASDAQ

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)1.42

Intrinsic Value $169.98median of 6 methods · middle span $101-$234based on filings through 30 Jun 2026

Market Price $145.35Price as of 30 Sep 2026

UndervaluedIntrinsic value is 17% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $10.3B

Enterprise Value $9.3B

Shares Outstanding 71.1M diluted

Moat Rating Narrow

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Align's record second-quarter Clear Aligner shipments, 8.2% year-over-year Clear Aligner revenue growth, international expansion, improving non-GAAP margin outlook, substantial cash balance, and increased repurchase commitment support the long-term digital-dentistry thesis. The counterweight is weak Systems and Services revenue, lower-priced scanner and leasing mix, restructuring execution, foreign-exchange exposure, and the UK VAT contingency.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$170.00

Mean target$208.60

High · most bullish analyst$240.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$170.0022%

Discretionary dental demand weakens, Clear Aligner growth falls below management's outlook, and the lower-priced scanner and leasing transition fails to generate enough downstream treatment or recurring revenue. UK VAT, legal, restructuring, foreign-exchange, and product-mix pressures then prevent the expected margin expansion.

Base CaseCentral scenario

$208.6058%

Matches the consensus mean

Align broadly achieves its 3% to 4% fiscal 2026 revenue-growth outlook, approximately 6% Clear Aligner volume growth, and approximately 23.7% non-GAAP operating margin. Clear Aligner momentum and cost discipline offset continued Systems and Services softness, while the strategic review supports incremental fiscal 2027 margin improvement.

Bull CaseUpside scenario

$240.0020%

Clear Aligner growth remains durable across international regions and customer channels; expanding scanner placements enlarge the digital-platform funnel despite lower upfront scanner revenue; and the strategic operating-model review produces commercial improvements and margin expansion beyond the fiscal 2026 and preliminary fiscal 2027 objectives. Increased repurchases amplify per-share participation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Q2 2026 Clear Aligner revenue increased 8.2% year over year and shipments reached a record 691,785 cases, with double-digit expansion across APAC, EMEA, and Latin America.
Management maintained fiscal 2026 worldwide revenue-growth guidance of 3% to 4% and expects approximately 100 basis points of non-GAAP operating-margin improvement, with at least approximately another 100 basis points targeted for fiscal 2027.
The company ended Q2 2026 with approximately $1.1 billion of cash and increased its planned 2026 share repurchases to $400 million to $500 million.

Key Investment Risks

Q2 2026 Imaging Systems and CAD/CAM Services revenue declined 10.8% year over year as capital-equipment demand remained soft and product mix shifted toward lower-priced scanners, leasing, and rental models.
The UK Upper Tribunal ruling led Align to record an estimated $37.5 million VAT liability, including interest, and UK VAT is scheduled to apply to relevant invoices beginning September 7, 2026.
Fiscal 2026 guidance incorporates $90 million to $110 million of one-time charges affecting GAAP operating margin, principally restructuring, accelerated depreciation, and legal settlements.
Results remain exposed to foreign-exchange movements, discretionary patient demand, competition, tariffs, and uncertainty over whether greater scanner adoption converts into higher-margin treatment revenue.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.